Global Leukemia Therapeutics Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

  • receipt Report ID : 147495
  • calendar_today Published On: Apr, 2019
  • file_copy Pages: 128
  • list Pharmaceuticals and Healthcare

Leukemia is a group of cancers that usually begin in the bone marrow and result in high numbers of abnormal white blood cells.

Scope of the Report:

This report focuses on the Leukemia Therapeutics in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

The worldwide market for Leukemia Therapeutics is expected to grow at a CAGR of roughly 3.6% over the next five years, will reach 12500 million US$ in 2023, from 10100 million US$ in 2017, according to a new GIR (Global Info Research) study.

Market Segment by Manufacturers, this report covers

Roche

GlaxoSmithKline

Novartis

Bristol-Myers Squibb

Eisai

Biogen Idec

ERYtech Pharma

Celgene

Genmab

Cephalon

Clavis Pharma

Pfizer

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Gleevec

Sprycel

Tasigna

Clolar

Others

Market Segment by Applications, can be divided into

Hospital

Clinic

There are 15 Chapters to deeply display the global Leukemia Therapeutics market.

Chapter 1, to describe Leukemia Therapeutics Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Leukemia Therapeutics, with sales, revenue, and price of Leukemia Therapeutics, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Leukemia Therapeutics, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Leukemia Therapeutics market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Leukemia Therapeutics sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Market Overview

1.1 Leukemia Therapeutics Introduction

1.2 Market Analysis by Type

1.2.1 Gleevec

1.2.2 Sprycel

1.2.3 Tasigna

1.2.4 Clolar

1.2.5 Others

1.3 Market Analysis by Applications

1.3.1 Hospital

1.3.2 Clinic

1.4 Market Analysis by Regions

1.4.1 North America (United States, Canada and Mexico)

1.4.1.1 United States Market States and Outlook (2013-2023)

1.4.1.2 Canada Market States and Outlook (2013-2023)

1.4.1.3 Mexico Market States and Outlook (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy)

1.4.2.1 Germany Market States and Outlook (2013-2023)

1.4.2.2 France Market States and Outlook (2013-2023)

1.4.2.3 UK Market States and Outlook (2013-2023)

1.4.2.4 Russia Market States and Outlook (2013-2023)

1.4.2.5 Italy Market States and Outlook (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.3.1 China Market States and Outlook (2013-2023)

1.4.3.2 Japan Market States and Outlook (2013-2023)

1.4.3.3 Korea Market States and Outlook (2013-2023)

1.4.3.4 India Market States and Outlook (2013-2023)

1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)

1.4.4 South America, Middle East and Africa

1.4.4.1 Brazil Market States and Outlook (2013-2023)

1.4.4.2 Egypt Market States and Outlook (2013-2023)

1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)

1.4.4.4 South Africa Market States and Outlook (2013-2023)

1.4.4.5 Nigeria Market States and Outlook (2013-2023)

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

2 Manufacturers Profiles

2.1 Roche

2.1.1 Business Overview

2.1.2 Leukemia Therapeutics Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Roche Leukemia Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.2 GlaxoSmithKline

2.2.1 Business Overview

2.2.2 Leukemia Therapeutics Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 GlaxoSmithKline Leukemia Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.3 Novartis

2.3.1 Business Overview

2.3.2 Leukemia Therapeutics Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Novartis Leukemia Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.4 Bristol-Myers Squibb

2.4.1 Business Overview

2.4.2 Leukemia Therapeutics Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Bristol-Myers Squibb Leukemia Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.5 Eisai

2.5.1 Business Overview

2.5.2 Leukemia Therapeutics Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Eisai Leukemia Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.6 Biogen Idec

2.6.1 Business Overview

2.6.2 Leukemia Therapeutics Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Biogen Idec Leukemia Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.7 ERYtech Pharma

2.7.1 Business Overview

2.7.2 Leukemia Therapeutics Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 ERYtech Pharma Leukemia Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.8 Celgene

2.8.1 Business Overview

2.8.2 Leukemia Therapeutics Type and Applications

2.8.2.1 Product A

2.8.2.2 Product B

2.8.3 Celgene Leukemia Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.9 Genmab

2.9.1 Business Overview

2.9.2 Leukemia Therapeutics Type and Applications

2.9.2.1 Product A

2.9.2.2 Product B

2.9.3 Genmab Leukemia Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.10 Cephalon

2.10.1 Business Overview

2.10.2 Leukemia Therapeutics Type and Applications

2.10.2.1 Product A

2.10.2.2 Product B

2.10.3 Cephalon Leukemia Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.11 Clavis Pharma

2.11.1 Business Overview

2.11.2 Leukemia Therapeutics Type and Applications

2.11.2.1 Product A

2.11.2.2 Product B

2.11.3 Clavis Pharma Leukemia Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.12 Pfizer

2.12.1 Business Overview

2.12.2 Leukemia Therapeutics Type and Applications

2.12.2.1 Product A

2.12.2.2 Product B

2.12.3 Pfizer Leukemia Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

3 Global Leukemia Therapeutics Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)

3.1 Global Leukemia Therapeutics Sales and Market Share by Manufacturer (2016-2017)

3.2 Global Leukemia Therapeutics Revenue and Market Share by Manufacturer (2016-2017)

3.3 Market Concentration Rate

3.3.1 Top 3 Leukemia Therapeutics Manufacturer Market Share in 2017

3.3.2 Top 6 Leukemia Therapeutics Manufacturer Market Share in 2017

3.4 Market Competition Trend

4 Global Leukemia Therapeutics Market Analysis by Regions

4.1 Global Leukemia Therapeutics Sales, Revenue and Market Share by Regions

4.1.1 Global Leukemia Therapeutics Sales and Market Share by Regions (2013-2018)

4.1.2 Global Leukemia Therapeutics Revenue and Market Share by Regions (2013-2018)

4.2 North America Leukemia Therapeutics Sales and Growth Rate (2013-2018)

4.3 Europe Leukemia Therapeutics Sales and Growth Rate (2013-2018)

4.4 Asia-Pacific Leukemia Therapeutics Sales and Growth Rate (2013-2018)

4.5 South America Leukemia Therapeutics Sales and Growth Rate (2013-2018)

4.6 Middle East and Africa Leukemia Therapeutics Sales and Growth Rate (2013-2018)

5 North America Leukemia Therapeutics by Countries

5.1 North America Leukemia Therapeutics Sales, Revenue and Market Share by Countries

5.1.1 North America Leukemia Therapeutics Sales and Market Share by Countries (2013-2018)

5.1.2 North America Leukemia Therapeutics Revenue and Market Share by Countries (2013-2018)

5.2 United States Leukemia Therapeutics Sales and Growth Rate (2013-2018)

5.3 Canada Leukemia Therapeutics Sales and Growth Rate (2013-2018)

5.4 Mexico Leukemia Therapeutics Sales and Growth Rate (2013-2018)

6 Europe Leukemia Therapeutics by Countries

6.1 Europe Leukemia Therapeutics Sales, Revenue and Market Share by Countries

6.1.1 Europe Leukemia Therapeutics Sales and Market Share by Countries (2013-2018)

6.1.2 Europe Leukemia Therapeutics Revenue and Market Share by Countries (2013-2018)

6.2 Germany Leukemia Therapeutics Sales and Growth Rate (2013-2018)

6.3 UK Leukemia Therapeutics Sales and Growth Rate (2013-2018)

6.4 France Leukemia Therapeutics Sales and Growth Rate (2013-2018)

6.5 Russia Leukemia Therapeutics Sales and Growth Rate (2013-2018)

6.6 Italy Leukemia Therapeutics Sales and Growth Rate (2013-2018)

7 Asia-Pacific Leukemia Therapeutics by Countries

7.1 Asia-Pacific Leukemia Therapeutics Sales, Revenue and Market Share by Countries

7.1.1 Asia-Pacific Leukemia Therapeutics Sales and Market Share by Countries (2013-2018)

7.1.2 Asia-Pacific Leukemia Therapeutics Revenue and Market Share by Countries (2013-2018)

7.2 China Leukemia Therapeutics Sales and Growth Rate (2013-2018)

7.3 Japan Leukemia Therapeutics Sales and Growth Rate (2013-2018)

7.4 Korea Leukemia Therapeutics Sales and Growth Rate (2013-2018)

7.5 India Leukemia Therapeutics Sales and Growth Rate (2013-2018)

7.6 Southeast Asia Leukemia Therapeutics Sales and Growth Rate (2013-2018)

8 South America Leukemia Therapeutics by Countries

8.1 South America Leukemia Therapeutics Sales, Revenue and Market Share by Countries

8.1.1 South America Leukemia Therapeutics Sales and Market Share by Countries (2013-2018)

8.1.2 South America Leukemia Therapeutics Revenue and Market Share by Countries (2013-2018)

8.2 Brazil Leukemia Therapeutics Sales and Growth Rate (2013-2018)

8.3 Argentina Leukemia Therapeutics Sales and Growth Rate (2013-2018)

8.4 Colombia Leukemia Therapeutics Sales and Growth Rate (2013-2018)

9 Middle East and Africa Leukemia Therapeutics by Countries

9.1 Middle East and Africa Leukemia Therapeutics Sales, Revenue and Market Share by Countries

9.1.1 Middle East and Africa Leukemia Therapeutics Sales and Market Share by Countries (2013-2018)

9.1.2 Middle East and Africa Leukemia Therapeutics Revenue and Market Share by Countries (2013-2018)

9.2 Saudi Arabia Leukemia Therapeutics Sales and Growth Rate (2013-2018)

9.3 UAE Leukemia Therapeutics Sales and Growth Rate (2013-2018)

9.4 Egypt Leukemia Therapeutics Sales and Growth Rate (2013-2018)

9.5 Nigeria Leukemia Therapeutics Sales and Growth Rate (2013-2018)

9.6 South Africa Leukemia Therapeutics Sales and Growth Rate (2013-2018)

10 Global Leukemia Therapeutics Market Segment by Type

10.1 Global Leukemia Therapeutics Sales, Revenue and Market Share by Type (2013-2018)

10.1.1 Global Leukemia Therapeutics Sales and Market Share by Type (2013-2018)

10.1.2 Global Leukemia Therapeutics Revenue and Market Share by Type (2013-2018)

10.2 Gleevec Sales Growth and Price

10.2.1 Global Gleevec Sales Growth (2013-2018)

10.2.2 Global Gleevec Price (2013-2018)

10.3 Sprycel Sales Growth and Price

10.3.1 Global Sprycel Sales Growth (2013-2018)

10.3.2 Global Sprycel Price (2013-2018)

10.4 Tasigna Sales Growth and Price

10.4.1 Global Tasigna Sales Growth (2013-2018)

10.4.2 Global Tasigna Price (2013-2018)

10.5 Clolar Sales Growth and Price

10.5.1 Global Clolar Sales Growth (2013-2018)

10.5.2 Global Clolar Price (2013-2018)

10.6 Others Sales Growth and Price

10.6.1 Global Others Sales Growth (2013-2018)

10.6.2 Global Others Price (2013-2018)

11 Global Leukemia Therapeutics Market Segment by Application

11.1 Global Leukemia Therapeutics Sales Market Share by Application (2013-2018)

11.2 Hospital Sales Growth (2013-2018)

11.3 Clinic Sales Growth (2013-2018)

12 Leukemia Therapeutics Market Forecast (2018-2023)

12.1 Global Leukemia Therapeutics Sales, Revenue and Growth Rate (2018-2023)

12.2 Leukemia Therapeutics Market Forecast by Regions (2018-2023)

12.2.1 North America Leukemia Therapeutics Market Forecast (2018-2023)

12.2.2 Europe Leukemia Therapeutics Market Forecast (2018-2023)

12.2.3 Asia-Pacific Leukemia Therapeutics Market Forecast (2018-2023)

12.2.4 South America Leukemia Therapeutics Market Forecast (2018-2023)

12.2.5 Middle East and Africa Leukemia Therapeutics Market Forecast (2018-2023)

12.3 Leukemia Therapeutics Market Forecast by Type (2018-2023)

12.3.1 Global Leukemia Therapeutics Sales Forecast by Type (2018-2023)

12.3.2 Global Leukemia Therapeutics Market Share Forecast by Type (2018-2023)

12.4 Leukemia Therapeutics Market Forecast by Application (2018-2023)

12.4.1 Global Leukemia Therapeutics Sales Forecast by Application (2018-2023)

12.4.2 Global Leukemia Therapeutics Market Share Forecast by Application (2018-2023)

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.1.3 Marketing Channel Future Trend

13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Data Source

List of Tables and Figures

Figure Leukemia Therapeutics Picture

Table Product Specifications of Leukemia Therapeutics

Figure Global Sales Market Share of Leukemia Therapeutics by Types in 2017

Please fill the form below, to recieve the report sample


+1

Choose License Type

Reach Us

Email us at

sales@mrinsights.biz

Or call us on

US +1-201-465-4211

IND +91-906-779-0957

Why Choose Us

ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems

Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach6 Major regions and 40+ countries level analysis accomplished

Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery